The short answer: if you cannot take hormone therapy, after a hormone-sensitive breast cancer, for example, or you prefer not to, there are real, evidence-based options that reduce hot flashes (hot flushes), night sweats and the sleep and mood fallout that come with them. The best-supported non-hormonal menopause treatments, according to The Menopause Society (2023), are certain antidepressants (SSRIs and SNRIs such as venlafaxine, paroxetine and escitalopram), which typically start to work within two weeks; the newer drug fezolinetant (Veoza), which targets the brain circuit behind flushes directly; gabapentin; and cognitive behavioural therapy, which NICE (2024) recommends considering for flushes, sleep problems and low mood. Oxybutynin is another option, while clonidine is no longer recommended by The Menopause Society. Weight loss may also help some women. None is as effective as estrogen (oestrogen), but several work well enough to change how you feel.
If you have searched “what can I take if I can’t have HRT” at 3am after soaking another set of sheets, you are not being dramatic. When hormones are taken off the table it can feel like the one door that helps has closed. It has not. The Menopause Society 2023 nonhormone therapy position statement reviewed the evidence and recommended several options, and this guide walks through what each one does, how strong the evidence is, and where the honest limits are.
Why might I need a non-hormonal option?
The most common reason is a personal or family history of a hormone-sensitive cancer, breast cancer above all. If a tumour was fuelled by oestrogen, adding oestrogen back carries a risk most oncologists will not accept, and drugs like tamoxifen can cause or worsen flushes at the same time. The NHS also lists some liver conditions and a history of blood clots among the reasons some forms of HRT may not be suitable.
Some women have tried HRT and did not get on with it. And many prefer not to take hormones, for reasons that are theirs to hold. Whatever the route in, the goal is the same: to treat the symptoms that are disrupting your life without using systemic oestrogen.
It helps to be clear on terms first. “Non-hormonal” here means treatments that do not add oestrogen or progesterone to your body, so they work through the brain, the nervous system or your daily habits rather than by replacing the hormone you have lost.
Which non-hormonal treatments work best? The options at a glance
The Menopause Society (2023) rates the evidence as good and consistent for SSRIs and SNRIs, fezolinetant, gabapentin and CBT, and as good to limited for oxybutynin. It does not recommend clonidine. Because the right option depends on which symptoms trouble you most and what else is going on in your health, it helps to see them side by side.
| Treatment | What it helps most | Evidence strength |
|---|---|---|
| SSRIs/SNRIs (venlafaxine, paroxetine, escitalopram) | Hot flashes, night sweats | Good |
| Fezolinetant (Veoza) | Moderate to severe hot flashes and night sweats | Good, newer |
| Cognitive behavioural therapy (CBT) | How much flushes bother you, sleep, low mood | Good |
| Gabapentin | Hot flashes; night-time dosing may suit disrupted sleep | Good |
| Oxybutynin | Moderate to severe hot flashes | Good to limited |
| Clonidine | Hot flashes | Modest; not recommended by The Menopause Society |
| Vaginal (local) oestrogen | Vaginal dryness, discomfort, urinary symptoms | Recommended by NICE; minimal absorption |
SSRIs for hot flashes (hot flushes): do antidepressants really help?
Yes. Certain SSRIs and SNRIs reduce hot flashes in large randomised trials, and the one FDA-approved version, low-dose paroxetine, uses a dose lower than those used for depression. According to The Menopause Society (2023 nonhormone therapy position statement), SSRIs and SNRIs are recommended, evidence-based non-hormonal options for vasomotor symptoms, with mild to moderate improvements. In the UK, NICE (NG23) advises that they are not routinely offered as the first treatment for flushes alone.
You do not need to be depressed to be prescribed one for flushes, and being offered one does not mean a clinician thinks the symptom is “in your head”. For the symptom itself and why it happens, see our guide to hot flushes in menopause.
How do SSRIs and SNRIs reduce hot flashes?
They do not change your oestrogen levels, and exactly how they ease flushes is not fully understood; the FDA label for low-dose paroxetine describes the mechanism as unknown. Hot flashes are linked to changes in the temperature-control centre in the hypothalamus as oestrogen falls. Serotonin and noradrenaline, the chemical messengers these drugs act on, are thought to play a part in how that centre sets your body’s “comfortable temperature” range.
One theory is that adjusting those signals makes the body less likely to overreact to small temperature shifts with a full flush.
Which SSRIs and SNRIs have the best evidence?
According to The Menopause Society (2023), paroxetine, escitalopram, citalopram, venlafaxine and desvenlafaxine have each been shown to significantly reduce hot flashes in large, double-blind randomised trials. Low-dose paroxetine (paroxetine mesylate, 7.5mg), approved by the FDA in 2013, is the only antidepressant approved in the US specifically for moderate-to-severe hot flashes. Venlafaxine, an SNRI, is one of the agents with large-trial evidence. Fluoxetine and sertraline showed only trends towards improvement that were not statistically significant, so The Menopause Society does not recommend them for flushes.
| Medication | Class | Evidence for hot flashes | Notes and cautions |
|---|---|---|---|
| Paroxetine (mesylate) | SSRI | Good; FDA-approved for this use at a low dose | Avoided with tamoxifen; can interact with other drugs |
| Venlafaxine | SNRI | Good | Caution with poorly controlled blood pressure |
| Escitalopram | SSRI | Good | Less effect on tamoxifen than paroxetine |
| Citalopram | SSRI | Good | Dose limits apply for heart-rhythm safety |
| Desvenlafaxine | SNRI | Good | Similar profile to venlafaxine |
This table is a general reference, not a prescription. These medicines are prescribed and reviewed by a clinician, and the choice and dose depend on your history, your other medications and what a prescriber judges safe for you. The Menopause Society lists these agents among recommended non-hormonal choices, and the British Menopause Society’s prescribable alternatives to HRT tool (reviewed 2026) includes paroxetine, citalopram, escitalopram and venlafaxine.
How well do they work compared with HRT?
They help, but oestrogen remains the most effective treatment for hot flashes, and that comparison deserves honesty. The Menopause Society (2023) notes that estradiol would be expected to improve hot flashes by around 77 percent on average, and calls hormone therapy the most effective treatment. For SSRIs and SNRIs, it reports hot flash reductions ranging from 25 to 69 percent across trials, which it describes as mild to moderate improvements.
Expect a meaningful reduction rather than elimination. For many women, especially those who cannot use hormones, that reduction is still the gap between coping and not coping. The point of non-hormonal medication is not that it beats oestrogen; it is that it gives you a genuine option when oestrogen is not available or not wanted.
If you are still weighing hormones and want that evidence laid out, read HRT for menopause explained and our review of whether HRT is safe on the 2026 evidence.
How quickly do SSRIs work for hot flashes?
Faster than they work for mood, which surprises people. For depression, the NHS says antidepressants usually take one to two weeks to start having an effect and up to eight weeks to work fully. For hot flashes, The Menopause Society (2023) says non-hormonal prescription treatments typically start to work within two weeks.
That quicker timeline is a useful signal. If you have been on a low dose for three to four weeks with no change in your flushes, raise it with your clinician rather than quietly waiting it out, because a different agent or a dose adjustment may be the answer.
What are the side effects, and why does tamoxifen matter?
The NHS notes that many side effects ease after a couple of weeks, and The Menopause Society (2023) says nausea or dizziness typically improves after one to two weeks. Common effects listed by the NHS include feeling sick, dry mouth, headaches, difficulty sleeping and loss of appetite. Antidepressants can also lower sex drive or make orgasm more difficult, which can feel like a cruel trade at a time when intimacy may already have shifted.
The interaction that matters most is with tamoxifen, a drug many women take after oestrogen-receptor-positive breast cancer. The Menopause Society (2023) explains that SSRIs can block CYP2D6, the liver enzyme that converts tamoxifen into its most active form, particularly paroxetine and fluoxetine, and the British Menopause Society notes this may make tamoxifen less effective. The Menopause Society names venlafaxine, desvenlafaxine, escitalopram and citalopram as safer choices for women on tamoxifen because they have less effect on that enzyme, though any choice should be agreed with the oncology team.
Stopping suddenly can cause withdrawal symptoms such as dizziness, irritability, headaches or aching muscles, which is why the NHS advises reducing the dose gradually with a doctor rather than stopping abruptly. None of this is a reason to rule them out; it is a reason to have the full conversation with someone who knows your history.
What is fezolinetant (Veoza), and is it worth asking about?
Fezolinetant was the first drug of its kind: the FDA describes it as the first neurokinin-3 (NK3) receptor antagonist approved for hot flashes. It acts directly on the brain circuit in the hypothalamus that disrupts temperature control when oestrogen falls, the mechanism behind a hot flash, and it is not a hormone. The FDA approved it in May 2023 for moderate to severe hot flashes caused by menopause. It is also licensed in the UK as Veoza, where the MHRA’s Drug Safety Update (2025) sets out liver function tests before and during treatment.
In its 12-week trials it reduced moderate to severe flushes more than placebo, and The Menopause Society (2023) rates its evidence as good and consistent. The honest caveats matter here. It treats flushes and night sweats, not the full range of menopause symptoms, and it is not a substitute for local treatment of vaginal symptoms.
It also carries an FDA boxed warning (added in 2024) about rare but serious liver injury, so liver blood tests are recommended before starting and at intervals during the first months of treatment. For a woman who cannot take hormones and whose main problem is flushing, it is an option to raise alongside SSRIs and SNRIs. Availability and cost still vary by country.
Does CBT really work for hot flashes?
It does, and this surprises people who assume talking therapy only touches mood. The Menopause Society (2023) rates the evidence for cognitive behavioural therapy as good and consistent. It does not necessarily reduce how many flushes you have, but it has been shown to reduce how much they bother you and how much they interfere with daily life. NICE guideline NG23 (2024 update) recommends considering menopause-specific CBT for hot flushes, for sleep problems linked to night sweats and for low mood linked to menopause.
The approach is practical. Menopause CBT programmes teach how thoughts and emotions affect the way physical sensations are felt, alongside strategies for managing flushes, triggers and sleep. Structured menopause-specific CBT programmes exist, delivered in groups, self-guided or online, which NICE notes as options. It carries no drug interactions, and The Menopause Society notes trials showing benefit in breast cancer survivors.
What about gabapentin, clonidine and oxybutynin?
These are the second-line prescription options, useful when the first choices are not tolerated or not enough. Gabapentin, an epilepsy and nerve-pain medicine, has good evidence for reducing the frequency and severity of flushes, and The Menopause Society (2023) notes that because drowsiness is a side effect, bedtime dosing may suit women whose sleep is disrupted by night sweats. Oxybutynin, a bladder medication, has been shown to reduce moderate to severe hot flashes, though it can cause dry mouth, and long-term use may be linked to cognitive decline in older people.
Clonidine, a blood-pressure drug, is modestly better than placebo but less effective than SSRIs, SNRIs and gabapentin, and side effects like dry mouth, low blood pressure and drowsiness limit it. The Menopause Society (2023) no longer recommends it for flushes. All three are decisions to make with a practitioner who knows your full history, and clonidine in particular should not be stopped suddenly because blood pressure can rise sharply. A wider look at what does and does not have evidence, including over-the-counter products, is in our guide to menopause supplements.
One important exception: vaginal oestrogen
Low-dose vaginal oestrogen is not the same as systemic HRT, and that distinction changes what is possible for many women. Systemic hormone therapy, the kind that treats whole-body symptoms, is what is usually avoided after a hormone-sensitive cancer. Local vaginal oestrogen is a low-dose cream, gel, tablet, pessary or ring that treats vaginal dryness, discomfort and urinary symptoms; NICE (2024) notes that only a minimal amount is absorbed into the bloodstream compared with systemic HRT.
For women with a history of breast cancer, NICE recommends offering non-hormonal moisturisers or lubricants first, and considering vaginal oestrogen if symptoms continue. It notes that for oestrogen receptor-positive cancer it is unknown whether the small amount absorbed affects recurrence risk, so this is a decision to make with your oncologist rather than assume. NICE also notes that symptoms often return when vaginal oestrogen is stopped.
The lifestyle levers that support everything else
Lifestyle changes will not match a well-chosen medication for severe flushes, and it is fair to be sceptical of advice that stops at “keep cool and cut caffeine” when you are drenched at 3am. The Menopause Society (2023) found no strong evidence that cooling techniques, such as layers, fans and a cooler bedroom, or avoiding triggers improve flushes, though they are low-risk ways to make yourself more comfortable.
Weight loss is the lifestyle change with the best support: The Menopause Society (2023) says it may be considered for improving flushes, particularly earlier in the transition. Exercise has other health benefits but has not been shown to reduce flushes, and paced breathing has not been shown to help them in trials. None of this replaces treatment you need.
How do I choose, and who can help?
Start from your main symptom, your medical history and how long you may need relief. Vasomotor symptoms last far longer than most women expect, a median total duration of 7.4 years according to the SWAN study (Avis and colleagues, JAMA Internal Medicine, 2015), so a treatment you can tolerate matters over years, not weeks. Our guide to how long hot flashes last explains why.
At Yellow (spotyellow.com), we think the real win is matching the option to your life and history rather than defaulting to one answer. If you want a practitioner who treats menopause and will take a non-hormonal plan seriously, our practitioner directory is a place to start, and our Symptom Impact Check can help you walk in with your flush pattern and triggers already mapped.
Frequently Asked Questions
What is the best non-hormonal treatment for hot flashes?
There is no single best option; it depends on your health and which symptoms trouble you most. The Menopause Society (2023) rates the evidence as good for certain SSRIs or SNRIs, fezolinetant, gabapentin and cognitive behavioural therapy. NICE suggests CBT can be used alongside other treatments. A clinician who knows your history can help you choose.
Can I take anything for menopause after breast cancer?
There are non-hormonal options. The Menopause Society (2023) notes CBT has shown benefit in breast cancer survivors, and names venlafaxine, desvenlafaxine, escitalopram and citalopram as safer choices than paroxetine or fluoxetine for women on tamoxifen. NICE says vaginal oestrogen can be considered for persistent vaginal symptoms. Every choice should be confirmed with your oncologist.
Can I take antidepressants for hot flashes if I’m not depressed?
Yes. Certain SSRIs and SNRIs reduce hot flashes in trials, and low-dose paroxetine is FDA-approved specifically for moderate to severe hot flashes at a dose lower than those used for depression. You do not need a depression diagnosis to be prescribed them for flushes. A clinician prescribes them and reviews how well they are working.
Why can’t I take paroxetine with tamoxifen?
Paroxetine blocks CYP2D6, the liver enzyme that converts tamoxifen into its most active form, which may make tamoxifen less effective after breast cancer. Fluoxetine has the same problem. The Menopause Society (2023) names venlafaxine, desvenlafaxine, escitalopram and citalopram as safer choices because they have less effect on that enzyme.
How long do SSRIs take to work for hot flashes?
Faster than they work for mood. The Menopause Society (2023) says non-hormonal prescription treatments for hot flashes typically start to work within two weeks. If nothing has changed after three to four weeks on a stable low dose, it is worth asking your clinician about adjusting the dose or trying a different agent.
Are SSRIs as effective as HRT for hot flashes?
Generally no. The Menopause Society (2023) calls hormone therapy the most effective treatment, with estradiol expected to improve hot flashes by around 77 percent, while SSRIs and SNRIs reduced them by 25 to 69 percent across trials. For women who cannot or prefer not to take hormones, that reduction can still make a real difference.
Is fezolinetant (Veoza) safe?
It is a non-hormonal treatment approved for moderate to severe hot flashes by the FDA in 2023 and licensed in the UK, where the MHRA has issued liver safety advice. The main concern is rare but serious liver injury, which carries an FDA boxed warning, so liver blood tests are recommended before starting and during the early months of treatment.
Further Reading
- The Menopause Society (formerly NAMS). The 2023 nonhormone therapy position statement. Menopause 2023;30(6):573-590. https://pubmed.ncbi.nlm.nih.gov/37252752/
- NICE. Menopause: identification and management (NG23). https://www.nice.org.uk/guidance/ng23
- British Menopause Society. Tool for clinicians: prescribable alternatives to HRT (reviewed March 2026). https://thebms.org.uk/wp-content/uploads/2026/03/02-NEW-BMS-Prescribable-alternatives-to-HRT-MARCH2026-A.pdf
- FDA. FDA approves novel drug to treat moderate to severe hot flashes caused by menopause (May 2023). https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause
- Avis NE et al. (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine 2015. https://pubmed.ncbi.nlm.nih.gov/25686030/
This article is for general information and does not constitute medical advice, and it is not a recommendation to take or avoid any medication or hormone therapy. Non-hormonal treatments have different risks, interactions and evidence levels, and the right choice and dose depend on your personal medical history, especially after breast cancer or other hormone-sensitive conditions. Please discuss any treatment with a qualified healthcare professional before starting, changing or stopping it.
